CY3
CY3 Dragon Pharma — Overview
CY3 Dragon Pharma is a three-compound oral thermogenic combining Clenbuterol HCl, Yohimbine HCl, and Liothyronine (T3) in a single 37 mcg tablet. Each active component targets fat loss through a distinct physiological mechanism: clenbuterol activates beta-2 adrenergic receptors to raise thermogenesis and metabolic rate; yohimbine blocks alpha-2 adrenergic receptors to unlock fat mobilization in stubborn storage areas; T3 directly accelerates overall metabolism through thyroid hormone signaling. The combination addresses fat loss from three non-overlapping angles simultaneously, which is the primary rationale for stacking all three rather than using any one alone.
CY3 is used during cutting phases and pre-contest preparation where body fat reduction is the primary goal. It is not a hormonal compound in the AAS sense and does not require PCT, but T3 suppresses endogenous thyroid production during use and requires a gradual taper upon discontinuation to allow the HPT axis to recover.
About the Compound: CY3
CY3 combines three agents with distinct mechanisms that target fat loss through separate but complementary pathways:
Clenbuterol HCl — a selective beta-2 adrenergic receptor agonist. Clenbuterol stimulates beta-2 receptors in adipose tissue, smooth muscle, and skeletal muscle. In fat tissue, beta-2 activation triggers the cAMP-mediated cascade that activates hormone-sensitive lipase, releasing stored triglycerides for oxidation. In skeletal muscle, beta-2 agonism exerts a mild anti-catabolic effect by reducing myofibrillar protein degradation, which is relevant during caloric deficits. Clenbuterol's thermogenic effect results in measurable body temperature elevation and increased oxygen consumption throughout the day. Its half-life of approximately 35 hours means once-daily dosing is sufficient for stable blood levels, but also means side effects persist for the full day if they occur. Desensitization of beta receptors develops over 2–3 weeks of continuous use, which is why 2-week on/off cycling is the standard protocol.
Yohimbine HCl — an alpha-2 adrenergic receptor antagonist. Alpha-2 receptors in adipose tissue act as a brake on lipolysis: when catecholamines (adrenaline, noradrenaline) stimulate fat breakdown, alpha-2 receptor activation simultaneously blunts that response, particularly in fat deposits with high alpha-2 receptor density. These "stubborn" fat areas — typically lower abdomen, thighs, and glutes — are resistant to standard caloric deficit because of disproportionately high alpha-2 density. Yohimbine blocks these receptors, allowing catecholamines (and clenbuterol's beta-2 activation) to drive lipolysis in those areas without the alpha-2 brake. Yohimbine also acts as a CNS stimulant by increasing central norepinephrine release. Its half-life is approximately 2 hours, meaning its stimulant and cardiovascular effects are concentrated in the first few hours after dosing.
Liothyronine (T3) — the active form of thyroid hormone. T3 regulates basal metabolic rate at the genomic level by binding to thyroid hormone receptors in cell nuclei, upregulating the expression of enzymes involved in thermogenesis, glucose oxidation, and fatty acid metabolism. Unlike the stimulant effects of clenbuterol and yohimbine, T3's action on metabolic rate is slower-onset and longer-lasting — it takes 24–72 hours to see measurable metabolic changes after a dose adjustment. Exogenous T3 suppresses the hypothalamic-pituitary-thyroid (HPT) axis: the pituitary reduces TSH output in response to elevated T3, which in turn reduces endogenous thyroid hormone production. This suppression is reversible, but requires a gradual T3 taper upon discontinuation rather than abrupt cessation, which can temporarily leave metabolic rate below baseline as the HPT axis recovers.
What CY3 Does
- Elevated basal metabolic rate — T3 drives genomic upregulation of metabolic enzymes, increasing how many calories the body burns at rest; clenbuterol adds a thermogenic layer through beta-2 stimulation; the combined effect on daily caloric expenditure is substantially greater than either compound alone and allows a larger deficit without equivalent caloric restriction
- Enhanced lipolysis across all fat depots — clenbuterol's beta-2 activation and yohimbine's alpha-2 blockade work simultaneously to maximize catecholamine-driven fat mobilization; yohimbine specifically addresses the alpha-2-rich stubborn fat areas where standard caloric deficit and cardio produce minimal results, making the CY3 combination more comprehensive in fat depot coverage than clenbuterol alone
- Muscle preservation during deficit — clenbuterol's anti-catabolic effect via beta-2 receptors in skeletal muscle reduces myofibrillar protein breakdown during caloric restriction; T3 at controlled doses maintains anabolic hormone signaling; the net result is that a greater proportion of weight lost comes from fat rather than lean tissue compared to unassisted caloric deficit
- Cardiovascular performance during cutting — clenbuterol improves bronchodilation and oxygen transport, which partially offsets the performance decline associated with caloric restriction; this translates to better-maintained training intensity during a cut, which supports both muscle retention and caloric expenditure from exercise
Who It's For
- Users in an active cutting phase — CY3 produces the most meaningful results when combined with a caloric deficit and adequate protein intake; it amplifies the rate of fat loss achievable at a given deficit rather than creating fat loss without dietary discipline; users already in a deficit gain the most from the metabolic and lipolytic effects of the stack
- Users targeting stubborn fat depots — the yohimbine component is specifically relevant for individuals whose fat loss has stalled in alpha-2-receptor-dense areas (lower abdomen, thighs, glutes) despite overall caloric deficit; these areas respond poorly to clenbuterol alone because of the alpha-2 braking mechanism, which yohimbine directly addresses
- Pre-contest athletes and physique competitors — CY3's three-mechanism approach makes it popular in the final 6–10 weeks before competition, where incremental fat loss without muscle loss is the priority; the combination of metabolic rate elevation, enhanced lipolysis, and anti-catabolism addresses the specific demands of contest prep
- Experienced thermogenic users — first-time users of stimulant-based fat burners should assess clenbuterol or yohimbine individually before combining all three components; the cardiovascular and CNS stimulant load of CY3 is significant and requires tolerance assessment; users who have used clenbuterol previously are better positioned to start CY3 at a measured dose
Combinations
CY3 is a complete thermogenic stack and is often run alone. The following Dragon Pharma products address specific goals that complement rather than duplicate CY3's mechanisms:
| Goal | Addition | Rationale |
|---|---|---|
| Endurance and fat oxidation (independent pathway) | GW-501516 Dragon Pharma | GW-501516 (Cardarine) is a PPAR-delta agonist that improves fat oxidation and endurance through a pathway completely separate from adrenergic or thyroid mechanisms; it preserves cardiovascular performance during the caloric restriction period and enhances training capacity, supporting both fat loss and muscle retention; it does not share any mechanism with CY3 components and does not add to the stimulant load |
| Appetite suppression | Sibutramine Dragon Pharma | Sibutramine is a norepinephrine-serotonin reuptake inhibitor that reduces appetite through central satiety signaling; it addresses caloric intake while CY3 addresses caloric expenditure; the combination of appetite suppression and elevated metabolic rate creates a larger effective deficit; note that sibutramine has its own cardiovascular stimulant effects and should be used cautiously alongside CY3's adrenergic load |
| Fat oxidation support / mitochondrial transport | L-Carnitine 500 Dragon Pharma | L-Carnitine shuttles long-chain fatty acids into mitochondria for beta-oxidation; with CY3 mobilizing fatty acids from adipose tissue, carnitine availability can become a rate-limiting step in their actual oxidation; supplementation at 1–2 g/day supports conversion of mobilized fat into energy rather than re-esterification |
| Extended thyroid support / HPT axis stability | T4 Dragon Pharma | T4 (levothyroxine) is the precursor to T3 and has a much longer half-life (~7 days); some users add low-dose T4 alongside T3 to provide a stable thyroid hormone base and reduce the metabolic variability that comes from relying solely on exogenous T3; T4 is also used during the taper phase to support HPT axis recovery as T3 dose is reduced |
| Injectable spot-reduction protocol | Helios Dragon Pharma | Helios is an injectable blend of clenbuterol and yohimbine designed for subcutaneous local injection targeting specific fat depots; it can be used alongside CY3 as a localized complement — the oral CY3 provides systemic thermogenic and metabolic effects while Helios targets specific areas directly; this is an advanced protocol requiring experience with subcutaneous injections |
Side Effects & Management
CY3's side effect profile combines the stimulant load of clenbuterol and yohimbine with the metabolic effects of T3. The most significant concern is cardiovascular: all three components elevate heart rate and sympathetic nervous system activity, creating additive cardiac load that requires monitoring, especially in users with pre-existing cardiovascular issues.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Tachycardia and palpitations | Clenbuterol's beta-1 spillover and yohimbine's norepinephrine-raising effect both increase heart rate; the combination produces a greater cardiac stimulant effect than either compound alone; heart rate elevation of 10–20 BPM above resting is typical; at higher doses, palpitations and irregular rhythm can occur; users with pre-existing cardiac conditions should not use CY3 | Resting heart rate monitoring daily before dosing; if resting HR exceeds 90–100 BPM, reduce dose or pause; for persistent elevations, Nebicard (Nebivolol) is a beta-1 selective blocker that controls heart rate without fully blocking the beta-2 thermogenic effect of clenbuterol; Amlip (Amlodipine) addresses blood pressure elevation; starting at the lowest effective dose and titrating up reduces the severity of cardiovascular onset effects |
| Anxiety, tremors, restlessness | Yohimbine raises central norepinephrine, producing anxiety, jitteriness, and tremor in susceptible users; clenbuterol amplifies this through adrenergic stimulation; these effects are most pronounced in the first 1–2 hours after dosing and diminish with adaptation over several days; high doses, caffeine intake, and pre-existing anxiety sensitivity all worsen this presentation | Eliminate caffeine and other stimulants while using CY3; dose in the morning only to avoid compounding with cortisol peaks; for users who are very sensitive to yohimbine, assess tolerance by starting with half a tablet; dose reduction is the most effective lever — cutting to 1 tab/day from 2 significantly reduces CNS stimulant effects while maintaining most metabolic benefit from the T3 component |
| Insomnia | All three components have stimulant or activating properties — clenbuterol and yohimbine raise sympathetic tone, while T3 increases metabolic rate; dosing in the afternoon or evening significantly disrupts sleep architecture; even morning dosing can impair sleep quality in sensitive users due to clenbuterol's 35-hour half-life | Dose all tablets before 10 AM; for residual sleep disruption despite morning dosing, Meloset (Melatonin) 3–5 mg before bed is the lowest-intervention first step; if insomnia persists, Hypnite (Eszopiclone) or Zopisign (Zopiclone) can be used short-term; dose reduction resolves the issue if sleep aids are insufficient |
| Muscle cramps | Clenbuterol depletes intracellular taurine and shifts electrolyte balance, producing muscle cramping particularly during exercise; this is a well-documented clenbuterol-specific side effect unrelated to yohimbine or T3; cramping typically affects calves, hamstrings, and hands and becomes more pronounced at higher clenbuterol doses | Taurine supplementation at 3–5 g/day effectively prevents clenbuterol-induced cramping for most users; adequate potassium intake (from food or electrolyte supplementation) addresses the electrolyte component; staying well hydrated reduces cramping severity; this side effect is entirely manageable with supplementation and rarely requires dose reduction |
| HPT axis suppression from T3 | Exogenous T3 suppresses TSH secretion from the pituitary, which in turn reduces endogenous thyroid hormone production; this suppression is dose-dependent and duration-dependent; upon abrupt discontinuation of T3, there is a temporary period where both exogenous T3 is gone and endogenous production has not recovered, potentially leaving the user with transiently low thyroid hormone and below-baseline metabolic rate | Taper T3 dose gradually over 1–2 weeks at cycle end rather than stopping abruptly (reduce by half a tablet every 3–5 days); keeping cycles to 6–8 weeks minimizes the depth of suppression; T4 Dragon Pharma can be used at low dose during the taper to provide a stable thyroid hormone base while the HPT axis recovers; most users see full HPT recovery within 4–6 weeks of cycle end |
| Elevated blood pressure | Yohimbine raises blood pressure through increased central norepinephrine and peripheral vasoconstriction; clenbuterol can also elevate BP at higher doses; T3-driven increase in cardiac output adds to the effect; users with baseline hypertension are at greater risk and should monitor BP closely | BP baseline before cycle; regular monitoring throughout; for elevated readings (systolic >140 mmHg), Amlip (Amlodipine) is a practical first-line option; Sartel (Telmisartan) is preferred when sustained BP management is needed; dose reduction of CY3 is the most direct lever |
References
| Source | Topic | Link |
|---|---|---|
| PubMed / Drug Testing and Analysis | Clenbuterol pharmacology — beta-2 adrenergic agonist activity, increased resting energy expenditure, increased fat oxidation, and skeletal-muscle mTOR phosphorylation in healthy men | Jessen et al., 2020 ↗ |
| PubMed / Res Sports Med | Yohimbine HCl pharmacology — alpha-2 adrenergic antagonist context, body-composition effects, and fat-loss outcomes in elite soccer players | Ostojic, 2006 ↗ |
| NCBI Bookshelf / StatPearls | Thyroid hormone and T3 physiology — basal metabolic rate, thermogenesis, nuclear thyroid receptor action, lipolysis context, and TRH/TSH negative feedback regulation | StatPearls: Physiology, Thyroid Hormone ↗ |
What is CY3?
CY3 is an oral blend of Clenbuterol, T3, and Yohimbine for fat loss; see What is Clenbuterol, Liothyronine Sodium, Yohimbine. It's for cutting—consult professionals for safe use.
What does CY3 do?
CY3 accelerates fat loss and enhances definition via thermogenesis; see Mechanism of Action. It delivers a shredded look—monitor with labs.
How long does CY3 stay in your system?
With half-lives of 36-48 hours (Clen), 2.5 days (T3), and 1-2 hours (Yohimbine), it's detectable for 4-7 days; see Mechanism of Action. Plan cycles—consult professionals.
How to use CY3?
Take 1-3 tabs/day, cycled 2 weeks on/off; see How to Use. Use with diet and monitoring—consult for tailored plans.
Is CY3 dangerous?
CY3 is safe with proper dosing and monitoring; see Side Effects. Manage risks with labs—consult professionals for safety.
How does CY3 10mg work?
CY3 10mg is believed to influence metabolic processes involved in energy utilization and calorie expenditure, making it a compound of interest in weight management research.
What are the main benefits of CY3 10mg?
Commonly discussed benefits include support for metabolic activity, increased energy expenditure, and assistance in achieving a leaner body composition.
What are the possible side effects of CY3 10mg?
Potential side effects may include increased body temperature, changes in energy levels, sweating, or other effects associated with elevated metabolic activity.
Related Products
